Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment

kuyucu, ersin; Hakyemez, Ömer Serdar; Bülbül, Ahmet Murat; güler, YASİN; kara, adnan; Say, Ferhat

doi:10.5455/medscience.2022.12.282

Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment

YASİN güler, (Baltalimanı Kemik Hastalıkları Eğitim ve Araştırma Hastanesi, Ortopedi ve Travmatoloji Kliniği, İstanbul, Türkiye)

Ersin KUYUCU, (Altınbaş Üniversitesi, Bahçelievler Medicalpark Hastanesi, Ortopedi ve Travmatoloji Anabilim Dalı, İstanbul, Türkiye)

Adnan KARA, (İstanbul Medipol Üniversitesi, Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, İstanbul, Türkiye)

Ömer Serdar Hakyemez, (İstanbul Medipol Üniversitesi, Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, İstanbul, Türkiye)

Ferhat SAY, (Samsun 19 Mayıs Üniversitesi, Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, Samsun, Türkiye)

Ahmet Murat Bülbül (ABM Eklem Sağlığı Merkezi, Ortopedi ve Travmatoloji Anabilim Dalı, İstanbul, Türkiye)

Medicine Science

12 4

Yıl: 2023 Cilt: 12 Sayı: 2 Sayfa Aralığı: 542 - 547 Metin Dili: İngilizce DOI: 10.5455/medscience.2022.12.282 İndeks Tarihi: 12-07-2023

Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment

Öz:

Osteoarthritis (OA) is a prevalent joint condition that affects areas such as the knee, hip, hand, and spine. In treating mild to moderate cases of OA, treatment options such as intraarticular corticosteroids, viscosupplementation, glucosamine and chondroitin sulfate, PRP, and IL-1Ra are commonly used. This study aimed to compare the effects of IL-1 receptor antagonist (IL-1Ra) and platelet-rich plasma (PRP) on patients with Kellgren-Lawrence (KG) stage 2-3 knee osteoarthritis in terms of Visual Analog Scale (VAS) and Knee injury and osteoarthritis outcome score (KOOS). Ninety patients with KG stage 2-3 knee primary osteoarthritis were divided into two groups, with one group receiving three intraarticular IL-1Ra injections and the other group receiving three PRP injections. VAS and KOOS scores were recorded at the beginning and after six months to evaluate clinical improvement. Both the IL-1Ra and PRP groups showed statistically significant improvement in all scores, including the VAS and KOOS. After six months, the KOOS score in the IL-1Ra group was significantly higher than the PRP group, while the first-year VAS score after treatment in the IL-1Ra group was significantly lower compared to the PRP group. The mean KOOS scores increased from 44.1 to 87.8 and 46.04 to 84.43 at the end of six months in both groups, while the mean VAS scores decreased from 7.27 to 1.02 and 7.29 to 1.71 in the IL-1Ra and PRP groups, respectively. Administering intra-articular IL-1Ra once a week for three weeks can effectively improve function and reduce pain in patients with Kellgren-Lawrence stage 2-3 osteoarthritis. However, more research is necessary to validate the use of IL-1 receptor antagonists in OA treatment.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Felson D, Naımark T, Anderson A, et al. The prevalence of knee osteoarthritis in the elderly. The framingham osteoarthritis study. Arthritis Rheum. 1987;30:914-8.
2. Fajardo M, Dı Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging. 2005;22:141-61.
3. Sanchez M, Anıtua E, Orıve G, et al. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med. 2009;39:345-54.
4. Goldring MB, Berenhaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res. 2004;427:37-46.
5. Pelletier JP, Martel-Pelletier J, Raynauld JP. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Rsx Ther. 2006;8:206-19.
6. Valdes AM, Spector TD. The clinical relevance of genetic susceptibility to osteoarthritis. Best Pract Res Clin Rheumatol. 2010;24:3-14.
7. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55.
8. Seckinger P, Klein-Nulend J, Alander C, et al. Natural and recombinant human Il-1 receptor antagonists block the effects of Il-1 on bone resorption and prostaglandin production. J Immunol. 1990;145:4181-4.
9. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind dose- ranging randomized placebo-controlled study of recombinant human Il-1 recetor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of genant and larsen Scores. Arthritis Rheum. 2000;43:1001-9.
10. Ajrawat P, Dwyer T, Chahal J. Autologous interleukin 1 receptor antagonist blood-derived products for knee osteoarthritis: a systematic review. Arthroscopy. 2019;35;2211-21.
11. Kellgren JH, Lawrance JS. Radiological assessment of osteoarhrosis. Ann Rheum Dis. 1957;16:494-502.
12. Anıtua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529-535.
13. Anıtua E, Andıa I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4- 15.
14. Meijer H, Reinecke J, Becker C, et al. The production of anti-inflammatory cytokines in whole blood by physicochemical induction. Inflammat Res. 2003;52:404-7.
15. Esenyel C, Demirhan M, Esenyel M, et al. Comparison of four different intra-articular injection sites in the knee: a cadaver study. Knee Surgery, Sports Traumatology, Arthroscopy. 2006;15:573-7.
16. Collins NJ, Prinsen CAC, Christensen R, et al. Knee injury and osteoarthritis outcome score (KOOS): systematic review and meta-analysis of measurement properties. Osteoarthritis Cartilage. 2016;24:1317-29.
17. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res. 1999;40:1-11.
18. Alsousou J, Thompson M, Hulley P, et al. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Jt Surg. 2009;91:987-96.
19. Andıa I, Sanchez M, Maffullı N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther. 2012;12:7-22.
20. Gobbı A, Karnatzıkos G, Mahajan V, et al. Platelet-rich plasma treatment in symptomatic patients with knee osteoarthritis: preliminary results in a group of active patients. Sports Health. 2012;4:162-72.
21. Fılardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol. Arthrosc. 2011;19:528-35.
22. Cerza F, Carnı S, Carcangıu A, et al. Comparison between hyaluronic acid and platelet-rich plasma, Intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med. 2012;40:2822-7.
23. Say F, Gürler D, Yener K, et al. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Acta Chir Orthop Traumatol Cech. 2013;80:278-83.
24. Chen AL, Desai P, Adler EM, et al. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg. 2002;84-A:1142-7.
25. Weiss E. Knee osteoarthritis, body mass index and pain: data from the osteoarthritis initiative. Rheumatology (Oxford). 2014;53:2095-9.
26. Cubukcu D, Sarsan A, Alkan H. Relationships between pain, function and radiographic findings in osteoarthritis of the knee. A cross-sectional study. Arthritis. 2012;2012:984060.
27. Henderson B, Thompson RC, Hardingham T, et al. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine. 1991;3:246-9.
28. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 1996;39:1535-44.
29. Zhang P, Zhong ZH, Yu HT, et al. Exogenous expression of IL-1Ra and TGF-β1 promotes in vivo repair in experimental rabbit osteoarthritis. Scand J Rheumatol. 2015;44:404-11.
30. Wang F, Liu J, Chen X, et al. IL-1β receptor antagonist (IL-1Ra) combined with autophagy inducer (TAT-Beclin1) is an effective alternative for attenuating extracellular matrix degradation in rat and human osteoarthritis chondrocytes. Arthritis Res Ther. 2019;21:171.
31. Baltzer AWA, Moser C, Jansen SA, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009;17:152-60.
32. Rutgers M, Saris DBF, Dhert WJA, et al. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther. 2010;12:114.
33. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double- blind, placebo-controlled study. Arthritis Rheum. 2009;61:344-52.
34. Auw Yang KG, Raijmakers NJH, Van Arkel ERA, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage. 2008;16:498-505.
35. Vangsness T, Chung MH, Woodell-May J. Stimulation of IL-1ra production from platelet-rich plasma. 54th Annual Meeting of the Orthopaedic Research Society. San Francisco, USA. 2002.

APA	güler Y, kuyucu e, kara a, Hakyemez Ö, Say F, Bülbül A (2023). Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. , 542 - 547. 10.5455/medscience.2022.12.282
Chicago	güler YASİN,kuyucu ersin,kara adnan,Hakyemez Ömer Serdar,Say Ferhat,Bülbül Ahmet Murat Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. (2023): 542 - 547. 10.5455/medscience.2022.12.282
MLA	güler YASİN,kuyucu ersin,kara adnan,Hakyemez Ömer Serdar,Say Ferhat,Bülbül Ahmet Murat Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. , 2023, ss.542 - 547. 10.5455/medscience.2022.12.282
AMA	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. . 2023; 542 - 547. 10.5455/medscience.2022.12.282
Vancouver	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. . 2023; 542 - 547. 10.5455/medscience.2022.12.282
IEEE	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A "Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment." , ss.542 - 547, 2023. 10.5455/medscience.2022.12.282
ISNAD	güler, YASİN vd. "Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment". (2023), 542-547. https://doi.org/10.5455/medscience.2022.12.282

APA	güler Y, kuyucu e, kara a, Hakyemez Ö, Say F, Bülbül A (2023). Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. Medicine Science, 12(2), 542 - 547. 10.5455/medscience.2022.12.282
Chicago	güler YASİN,kuyucu ersin,kara adnan,Hakyemez Ömer Serdar,Say Ferhat,Bülbül Ahmet Murat Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. Medicine Science 12, no.2 (2023): 542 - 547. 10.5455/medscience.2022.12.282
MLA	güler YASİN,kuyucu ersin,kara adnan,Hakyemez Ömer Serdar,Say Ferhat,Bülbül Ahmet Murat Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. Medicine Science, vol.12, no.2, 2023, ss.542 - 547. 10.5455/medscience.2022.12.282
AMA	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. Medicine Science. 2023; 12(2): 542 - 547. 10.5455/medscience.2022.12.282
Vancouver	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment. Medicine Science. 2023; 12(2): 542 - 547. 10.5455/medscience.2022.12.282
IEEE	güler Y,kuyucu e,kara a,Hakyemez Ö,Say F,Bülbül A "Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment." Medicine Science, 12, ss.542 - 547, 2023. 10.5455/medscience.2022.12.282
ISNAD	güler, YASİN vd. "Short-term comparison of intraarticular administration of IL-1 receptor antagonist and platelet-rich plasma for osteoarthritis treatment". Medicine Science 12/2 (2023), 542-547. https://doi.org/10.5455/medscience.2022.12.282